For reporters & the curious
The paper trail behind the peptide story, in one place: the FDA's own actions and briefing documents, the federal docket, and peer-reviewed safety research. These are primary sources - please read and cite the originals. We add to this as the record grows.
The FDA's interim-policy list; several nominated peptides sit here with the agency's stated safety concerns (immunogenicity, peptide impurities, limited human safety data).
The FDA landing page explaining how the 503A bulks list and its categories work - the framework the July 2026 review sits inside.
States that drugs like retatrutide and cagrilintide cannot be lawfully compounded, and reports hundreds of adverse-event reports tied to compounded semaglutide and tirzepatide.
Documents hospitalizations from patients self-administering 5-20× the intended dose from multi-dose vials - a concrete example of the safety gap.
Cites an online seller offering retatrutide, semaglutide and tirzepatide as unapproved new and misbranded drugs.
Targets "research use only / not for human consumption" labeling on peptides sold to consumers - the exact grey-market dodge.
The official meeting page: the seven peptides under review, the uses evaluated, and downloadable FDA scientific briefing documents for each.
The authoritative process document establishing the meeting and the public comment docket.
The public docket where comments and background documents for the peptide review are posted.
Market-surveillance study of no-prescription online semaglutide; found measured purity far below label claims and quality-control failures.
Independent testing found purity from roughly 5-75% and arsenic and lead above injectable-drug limits in falsified peptide products.
Context on the policy push behind the review. Reported news, not a government document.
Overview of the advisory-committee review and the science debate around it.
Every link above resolves to its issuing organization. Peppies is independent and unaffiliated with the FDA; background-coverage items are clearly labeled as journalism, not primary sources. If a link ever breaks, tell us and we'll fix it.
Get notified
The vote is advisory. The decision that shapes access comes later - if and when the FDA opens a formal public comment window. Most people never hear it opened. Join the list and we'll tell you the instant it does, with step-by-step instructions to file a comment that counts.
